Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Circadian timing of tamoxifen in high-risk ER-positive/HER2-negative early breast cancer
PACTR202607871406155Not yet recruiting
- Sponsor
- Kafrelsheikh University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tamoxifen in breast cancer (2 arms), sponsored by Kafrelsheikh University. Primary endpoint: 5-year disease-free survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202607871406155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607871406155.